SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics IPO Watchlist Monthly Activity About API

SEC Comment Letter for Precipio, Inc. (PRPO) (CIK 0001043961) (PRPO) — Jan 21, 2020

Precipio, Inc. (PRPO) (CIK 0001043961)
Date: Jan. 21, 2020 · CIK: 0001043961 · Accession: 0000000000-20-000510

AI Filing Summary & Sentiment

File numbers found in text: 333-235911

Date
January 21, 2020
Author
Not clearly detected
Form
UPLOAD
Company
Precipio, Inc. (PRPO) (CIK 0001043961)

Letter

January 21, 2020 Ilan Danieli Chief Executive Officer Precipio, Inc. 4 Science Park New Haven, CT 06511 Re:Precipio, Inc. Registration Statement on Form S-1 Filed January 14, 2020 File No. 333-235911 Dear Mr. Danieli: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact William Mastrianna, Attorney-Adviser, at (202) 551-3778 or (202) 551- 2076 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Thomas Rose

Show Raw Text
January 21, 2020
Ilan Danieli
Chief Executive Officer
Precipio, Inc.
4 Science Park
New Haven, CT 06511
Re:Precipio, Inc.
Registration Statement on Form S-1
Filed January 14, 2020
File No. 333-235911
Dear Mr. Danieli:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration.  We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact William Mastrianna, Attorney-Adviser, at (202) 551-3778 or (202) 551-
2076 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Thomas Rose